Gene Editing Market | $7,305.5 Million Value by 2024 | CAGR of 14.7%

11/gen/2019 14:19:20 PBIGP Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

A Steady Growth In Global Gene Editing Market Due To Newer Launches And Demand By The Consumers

 Gene Editing Market 2017 to Boom $7,305.5 Million Value by 2024 at a CAGR of 14.7%

Changing aspects of gene editing Market

Factors which are leading the growth of gene editing market globally are-

·         Demand for personalized medicine

·         Increased cases of cancer and other genetic disorders

·         Increased companies investments in R &D

·         Growth of pharmaceutical and biotechnology industries

·         Increased funding with rapid advancements and various drug discovery applications.

Nonetheless, global gene editing market is hampered by strict government rules and regulations for approval, ethical issues, lack of awareness about the process and unavailability of gene editing therapeutics in the market.


Request Sample Report:


Market summary:

Gene editing market is heavily dominated by pharmaceutical and biotechnology sectors due to its drug discovery and therapeutics applications. Innovative research and development is what companies looking forward too, in addition to usage of CRISPR and ZFN. Many key market players are adopting strategies such as partnerships, collaborations, mergers and acquisitions which are driving the growth of genome editing market. An agreement was signed between Harvard (U.S), Institute of MIT and Sigma-Aldrich Corporation (U.S) to use CRISPR in 2014.


Regional analysis:

Due to strong presence of pharmaceuticals and biotechnology companies, North America dominates the gene editing market in global market.

Developing global regions such as Latin America and Asia-Pacific is growing at a substantial rate in the global genome editing market due to research and development in the regions with automation in laboratories and instrumentation which is leading to expansion of leading genome editing companies.


Notable market development:

European patent for Cellectis was granted the invention of genetically T-cells by adopting RNA-guided endonucleases (centromere and Promoter factor 1 (Cpf1) or CRISPR associated protein 9(Cas9)) in 2017.


Some of the key players in global genome editing market-

·         Cellectis S.A. (France)

·         Applied Stemcell, Inc. (U.S.)

·         Genscript (U.S.)

·         Merck KGaA (Germany)

·         Horizon Discovery Group plc,(U.K.)

·         Origene Technologies, Inc. (U.S.)

·         System Biosciences, Inc. (U.S.)

·         Sangamo Therapeutics, Inc.(U.S.)

·         Thermo Fisher Scientific (U.S)

·         Transposagen Biopharmaceuticals, Inc.(U.S.)


The global gene editing market is divided into following categories-

By technology

·         Zinc Finger Nuclease (ZFN)

·         Clustered regularly interspaced short palindromic repeats (CRISPR)

·         Transcription activator-like effector nuclease (TALEN)

·         Others

By application

·         Cell Line Editing

·         Targeted gene mutation

·         Animal Genome Editing

·         Plant Genome Editing

By product type

·         Consumables

·         Instruments and Software

By end-users

·         Pharmaceutical companies

·         Biotechnology Companies

·         Academics

·         Clinical Research Organizations

By geographical regions

·         North America

·         Latin America

·         Europe

·         Asia-Pacific

·         The Middle East & Africa


For More Information:


blog comments powered by Disqus è un servizio offerto da Factotum Srl